Ivonescimab in China: check the lung cancer indication first

Ivonescimab binds PD-1 and VEGF-A. It is an infused anticancer medicine, not CAR-T or a general treatment for every lung cancer.

Its Chinese approvals have expanded over time. A reviewing oncologist should verify the current product label and the exact regimen before discussing access.

China’s NMPA described the initial approval with pemetrexed and carboplatin for EGFR-mutated locally advanced or metastatic non-squamous NSCLC after progression on EGFR tyrosine kinase inhibitors.

Akeso has also announced approval for first-line monotherapy in PD-L1-positive, EGFR/ALK-negative NSCLC and, in August 2026, first-line ivonescimab plus chemotherapy for advanced squamous NSCLC. These are distinct pathways, not interchangeable regimens. A hospital must confirm the current label, tests and individual fit.

• Histology and stage, pathology slides or report, and recent CT or PET reports with images.
• EGFR, ALK and PD-L1 reports with methods and dates; other molecular results already available.
• Dated previous treatment lines, response, progression and adverse effects.
• Current medicines, symptoms, performance status and relevant bleeding or cardiovascular history.

Ask a specialist which approved regimen is being considered, whether another biopsy or molecular test is needed, and whether treatment could be better delivered near home. Confirm the appointment route before booking flights.

The hospital reviews pathology and biomarkers, chooses a regimen if appropriate, explains infusion scheduling and monitors response and adverse effects. The number of visits and duration depend on the plan and the patient’s condition.

Ask for consultation, pathology re-review, molecular tests, ivonescimab and any partner chemotherapy, infusion, scans, adverse-event care and follow-up as separate lines. Travel and MedRelay coordination need separate estimates.

PD-1 and VEGF-A targeting can bring immune-related and vascular adverse effects; chemotherapy adds its own risks when part of the regimen. The published HARMONi-2 trial reported serious treatment-related adverse events, so a specialist should discuss individual contraindications, monitoring and emergency plans.

Trial outcomes and regulatory approval cannot predict one patient’s response.

Depending on histology, biomarkers and treatment line, alternatives may include other approved immunotherapy, targeted therapy, chemotherapy, trials or supportive care. Ask why a specific regimen is preferred in this case.

We can organise existing reports and route a clear question to an appropriate hospital team, then coordinate practical planning. Clinical eligibility, treatment and outcome decisions belong to the hospital.